Table 1.
Combinational TRAIL treatments- Tumor cells
| Primary Tumour | TRAIL in combination with | Proposed mechanism | Reference |
|---|---|---|---|
| ALL | Vincristine (microtubule inhibitor) | [105] | |
| AML | HDAC inhibitor | [168] | |
| B-CLL | Cycloheximide | Downregulation of cFlipL | [171] |
| CLL | HDAC inhibitor | Signal via TRAIL-R1 | [166,167] |
| Colon cancer | Irinotecan, 5-FU | Upregulation of TRAIL-R2 | [172] |
| Erytholeukemic cells | Irradiation | Upregulation of TRAIL-R1 | [173] |
| Multiple myeloma | NF-κB inhibitor SN50 | Downregulation of Bcl-2, Bfl-1, IAPs, upregulalion of Bax | [163] |
| (Oligo-) astrocytoma | Bortezomib | Upregulation of TRAIL-R1/R2, Bax/Bak Downregulation of cFlipL | [174] |
| Pancreatic cancer | Gemtabicine, Doxorubicin, Cisplatin, Etoposide, Methotrexate | [175] | |
| Soft tissue sarcoma | Cyclophosphamide | [149] |